Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer

SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancing minimally invasive, anesthesia-free treatment approach PALO ALTO, Calif., May 1, 2026 /PRNewswire/ -- Sonire Therapeutics, a U.S.-based clinical-stage medical device company, today announced...